Johnson & Johnson (JNJ) Tops Q2 EPS by 3c, FY Guidance Misses Views

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.10, $0.03 better than the analyst estimate of $2.07. Revenue for the quarter came in at $20.8 billion versus the consensus estimate of $20.39 billion.

GUIDANCE:

Johnson & Johnson sees FY2018 EPS of $8.07-$8.17, versus the consensus of $8.12. Johnson & Johnson sees FY2018 revenue of $80.5-81.3 billion, versus the consensus of $81.47 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18